{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"175"}]}],"title":"Concomitant antibiotic prophylaxis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1261"}]}],"title":"No Concomitant antibiotic prophylaxis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1447"}],"units":"Participants"}],"description":"Objective 2: To describe EP2006 primary or secondary prophylaxis patterns for FN over up to 6 cycles of chemotherapy, with or without prior, concurrent, or later radiotherapy or surgery.","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"Concomitant Antibiotic Prophylaxis","type":"PRIMARY","unitOfMeasure":"participants"}